BTIG downgraded AnaptysBio (ANAB) to Neutral from Buy without a price target The company’s topline data from the Phase 2b trial of ANB032 in ...

Event Driven Strategies Analyst Lafranchi discusses the Berry Global (BERY)/Amcor (AMCRY) (AMCR) merger on an Analyst/Industry conference call ...

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 7.01% of ...

As of the latest trading close, VSTM, a Healthcare sector stock, is trading -62.59% below its 52-week high but remains 153.33% above its 52-week low. The Average True Range (ATR) (14 days) of 0.4 ...

Investing.com -- According to a note from BTIG on Monday, the tech sector's ongoing weakness is raising concerns as markets ...

Investors should start looking at restaurant names that have timely setups, said Jonathan Krinsky, chief market technician at ...

In footwear specifically, data from Jefferies found that 83 percent of the shoe retailers in its coverage saw Black Friday ...

Tech was leading the way lower for stocks Wednesday. BTIG Chief Market Technician Jonathan Krinsky noted that while tech ...

BTIG analyst Andrew Harte is praising MicroStrategy's (NASDAQ:MSTR) plan announced at the end of October to raise $42B of ...

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The firm says ONS-5010 did not surpass the 95% threshold for the primary ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...